Clinical Trial Update: Study of LMP1- and LMP2- Specific Cytotoxic T-Lymphocytes (CTL) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating LMP1- and LMP2-specific cytotoxic T lymphocytes for nasopharyngeal carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• LMP1- and LMP2-specific cytotoxic T lymphocytes

Snippet

Sponsor: Baylor College of Medicine | Conditions: NASOPHARYNGEAL CARCINOMA | Phase 1 | Status: WITHDRAWN